Literature DB >> 11897582

Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity.

Richard K Gaillard1, Jennifer Barnard, Vincent Lopez, Paula Hodges, Eric Bourne, Lance Johnson, Marchelle I Allen, Patrick Condreay, Wayne H Miller, Lynn D Condreay.   

Abstract

Mutations in the YMDD motif of the hepatitis B virus (HBV) DNA polymerase result in reduced susceptibility of HBV to inhibition by lamivudine, at a cost in replication fitness. The mechanisms underlying the effects of YMDD mutations on replication fitness were investigated using both a cell-based viral replication system and an in vitro enzyme assay to examine wild-type (wt) and YMDD-mutant polymerases. We calculated the affinities of wt and YMDD-mutant polymerases for each natural deoxyribonucleoside triphosphate (dNTP) and determined the intracellular concentrations of each dNTP in HepG2 cells under conditions that support HBV replication. In addition, inhibition constants for lamivudine triphosphate were determined for wt and YMDD-mutant polymerases. Relative to wt HBV polymerase, each of the YMDD-mutant polymerases showed increased apparent K(m) values for the natural dNTP substrates, indicating decreased affinities for these substrates, as well as increased K(i) values for lamivudine triphosphate, indicating decreased affinity for the drug. The effect of the differences in apparent K(m) values between YMDD-mutant polymerase and wt HBV polymerase could be masked by high levels of dNTP substrates (>20 microM). However, assays using dNTP concentrations equivalent to those measured in HepG2 cells under physiological conditions showed decreased enzymatic activity of YMDD-mutant polymerases relative to wt polymerase. Therefore, the decrease in replication fitness of YMDD-mutant HBV strains results from the lower affinities (increased K(m) values) of the YMDD-mutant polymerases for the natural dNTP substrates and physiological intracellular concentrations of dNTPs that are limiting for the replication of YMDD-mutant HBV strains.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897582      PMCID: PMC127103          DOI: 10.1128/AAC.46.4.1005-1013.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.

Authors:  S Kewn; P G Hoggard; S D Sales; M A Johnson; D J Back
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

2.  Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.

Authors:  C T Yeh; R N Chien; C M Chu; Y F Liaw
Journal:  Hepatology       Date:  2000-06       Impact factor: 17.425

Review 3.  Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.

Authors:  L J Stuyver; S A Locarnini; A Lok; D D Richman; W F Carman; J L Dienstag; R F Schinazi
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

Review 4.  Intracellular compartmentation of organelles and gradients of low molecular weight species.

Authors:  T Y Aw
Journal:  Int Rev Cytol       Date:  2000

Review 5.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

6.  In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy - a clinical note.

Authors:  B Zöllner; A Stoehr; A Plettenberg; H Feucht; M Schröter; P Schäfer; R Laufs
Journal:  J Clin Virol       Date:  2000-09-01       Impact factor: 3.168

7.  Deoxyribonucleotide pools during liver regeneration.

Authors:  S S Söderhäll; A Larsson; K L Skoog
Journal:  Eur J Biochem       Date:  1973-02-15

8.  Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.

Authors:  T Seta; O Yokosuka; F Imazeki; M Tagawa; H Saisho
Journal:  J Med Virol       Date:  2000-01       Impact factor: 2.327

9.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.

Authors:  S K Ono; N Kato; Y Shiratori; J Kato; T Goto; R F Schinazi; F J Carrilho; M Omata
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

10.  Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector.

Authors:  J P Condreay; S M Witherspoon; W C Clay; T A Kost
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

View more
  15 in total

1.  In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.

Authors:  Richard A Heipertz; Thomas G Miller; Colleen M Kelley; William E Delaney; Stephen A Locarnini; Harriet C Isom
Journal:  J Virol       Date:  2007-01-10       Impact factor: 5.103

Review 2.  Molecular mechanisms underlying HBsAg negativity in occult HBV infection.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-24       Impact factor: 3.267

Review 3.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

4.  The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.

Authors:  Nadia Warner; Stephen Locarnini; Michael Kuiper; Angeline Bartholomeusz; Anna Ayres; Lilly Yuen; Tim Shaw
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

5.  Inhibition of hepatitis B virus polymerase by entecavir.

Authors:  David R Langley; Ann W Walsh; Carl J Baldick; Betsy J Eggers; Ronald E Rose; Steven M Levine; A Jayne Kapur; Richard J Colonno; Daniel J Tenney
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

6.  Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy.

Authors:  Sun Young Lee; Moon Seok Choi; Dongho Lee; Joon Hyoek Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

7.  trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase.

Authors:  Richard A Heipertz; Jason L Starkey; Thomas G Miller; Jianming Hu; Harriet C Isom
Journal:  Virology       Date:  2009-04-19       Impact factor: 3.616

8.  Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance.

Authors:  Scott Preiss; Margaret Littlejohn; Peter Angus; Alex Thompson; Paul Desmond; Sharon R Lewin; Joe Sasadeusz; Gail Matthews; Gregory J Dore; Tim Shaw; Vitini Sozzi; Lilly Yuen; George Lau; Anna Ayres; Chloe Thio; Anchalee Avihingsanon; Kiat Ruxrungtham; Stephen Locarnini; Peter A Revill
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

9.  HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage.

Authors:  Ying Chen; Johnny Sze; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

10.  Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.

Authors:  Ann W Walsh; David R Langley; Richard J Colonno; Daniel J Tenney
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.